Literature DB >> 1437960

Bilateral carpal tunnel syndrome associated with interleukin 2 therapy.

S D Heys1, K L Mills, O Eremin.   

Abstract

We report the development of synchronous bilateral carpal tunnel syndrome in a woman with metastatic colorectal cancer, undergoing treatment with recombinant interleukin 2. A carpal tunnel decompression was carried out on the hand which was more severely affected, with a gradual recovery in median nerve function. To the best of our knowledge, this is the first reported case of carpal tunnel syndrome in association with recombinant interleukin 2.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1437960      PMCID： PMC2399391          DOI： 10.1136/pgmj.68.801.587

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  8 in total

1.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

2.  Reflections on 21 years' experience with the carpal-tunnel syndrome.

Authors:  G S Phalen
Journal:  JAMA       Date:  1970-05-25       Impact factor: 56.272

3.  Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.

Authors:  D E Webb; H A Austin; A Belldegrun; E Vaughan; W M Linehan; S A Rosenberg
Journal:  Clin Nephrol       Date:  1988-09       Impact factor: 0.975

4.  Clinical results of a cross-over treatment with pyridoxine and placebo of the carpal tunnel syndrome.

Authors:  J Ellis; K Folkers; T Watanabe; M Kaji; S Saji; J W Caldwell; C A Temple; F S Wood
Journal:  Am J Clin Nutr       Date:  1979-10       Impact factor: 7.045

5.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

Authors:  M Rosenstein; S E Ettinghausen; S A Rosenberg
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

6.  The carpal tunnel syndrome in hypertensive patients treated with beta-blockers.

Authors:  M K Emara; A M Saadah
Journal:  Postgrad Med J       Date:  1988-03       Impact factor: 2.401

7.  The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

Authors:  K D Denicoff; D R Rubinow; M Z Papa; C Simpson; C A Seipp; M T Lotze; A E Chang; D Rosenstein; S A Rosenberg
Journal:  Ann Intern Med       Date:  1987-09       Impact factor: 25.391

8.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245
  8 in total
  1 in total

Review 1.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.